康耐特光學(02276.HK)盈喜:預期上半年淨利增加不少於30%
格隆匯7月21日丨康耐特光學(02276.HK)公吿,預期集團於2023首半年的股東應占淨利潤將較截至2022年6月30日止6個月增加不少於30%。
此乃主要由於(i)2023首半年銷售業務持續拓展,產品銷量和銷售額有所增加;(ii)根據募集資金計劃的產能提升項目的建設實施後,效益逐漸凸顯,定製化鏡片及一站式服務的業務模式所帶來的銷售增幅相對較快,對總體銷售及利潤空間提升帶來幫助;(iii)財務費用利息支出的節約,合理優化了融資規模,同時降低融資成本;及(iv)國際匯率市場變動,美元升值帶來的匯兑收益增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.